Exuviance Singapore

re the initial collaboration between the two doctors started. Due to their common passion in the treatment of skin diseases, it led them to search for a compound that could instil positive influence on dry skin, ichthyosis, psoriasis, acne and other skin conditions involving disturbed keratinization. Alpha Hydroxy Acids was the discovery of the two doctors. It showed extremely promising results in the treatment of ichthyosis where patients returned with normal skin on areas where AHAs were applied. Embarking in deeper and more extensive research, their effort was paid off with the landmark publication in October 1974 Archives of Dermatology, where the newly discovered Alpha Hydroxy Acids were introduced to the dermatology community. Following the first publication, the doctors filed for their first patent for Alpha Hydroxy Acids, entitled Treatment of Ichthyosiform Dermatoses, dated April 22, 1975. Four decades since the initial discovery, AHAs are now still widely used in various formulations and applications by dermatologists and many skin care companies. Avon's Anew® in the early 1990s was the first cosmetic skin care product to license the anti-aging benefits of AHAs. Van Scott and Yu have licensed their inventions over the years to several companies including Bristol-Myers Squibb (Westwood Division), Avon, Chesebrough Ponds, L'Oreal, Medicis, Pfizer, Aventis, and many others. Till date, Drs. Eugene Van Scott and Ruey Yu own more than 110 patents, and have published close to 200 papers and over 50 papers respectively. Gluconolactone and Lactobionic acid were the 2nd and 3rd generation AHAs discovered to show better results as compared to the 1st generation AHAs in terms of treatment for photodamaged skin and sensitive skin.